Table 2.
Correlation Analyses of GlycA with various demographic and cardiometabolic variables in both cohorts
| A: Spearman correlation Analyses of GlycA in the PENN Cohort. | |||
|---|---|---|---|
| Parameter | Total Cohort (N=231) |
Psoriasis (N=122) |
Control (N=109) |
|
Demographic and Clinical Characteristics |
|||
| Age | 0.004 (NS) | 0.08 (NS) | 0.09 (NS) |
| Hypertension | 0.08 (NS) | 0.14 (NS) | 0.04 (NS) |
| Type 2 DM | 0.19 (<0.001) | 0.18 (NS) | No correlation |
| Smoker | 0.23 (<0.001) | 0.10 (NS) | 0.01 (NS) |
| Statin use | 0.07 (NS) | −0.07 (NS) | 0.06 (NS) |
| Clinical and Laboratory Values | |||
| Body Mass Index | 0.33 (<0.001) | 0.43 (<0.001) | 0.29 (<0.001) |
| Systolic blood pressure | 0.21 (<0.001) | 0.14 (NS) | 0.22 (<0.001) |
| Diastolic blood pressure | 0.17 (<0.001) | 0.11 (NS) | 0.21 (<0.001) |
| Total Cholesterol | 0.09 (<0.05) | 0.27 (<0.01) | 0.23 (<0.001) |
| Low-Density Lipoprotein cholesterol | −0.01 (NS) | 0.27 (<0.01) | 0.11 (<0.05) |
| High-Density Lipoprotein cholesterol | −0.08 (NS) | −0.16 (NS) | −0.01 (NS) |
| Triglycerides | 0.30 (<0.001) | 0.35 (<0.001) | 0.36 (<0.001) |
| Framingham risk score | 0.14 (<0.01) | 0.27 (<0.01) | 0.12 (<0.05) |
| Glucose mg/dl | −0.03 (NS) | 0.01 (NS) | 0.05 (NS) |
| Insulin | 0.48 (<0.001) | 0.17 (NS) | 0.25 (<0.001) |
| hsCRP | 0.45 (<0.001) | 0.73 (<0.01) | 0.44 (<0.001) |
| Psoriasis Characteristics | |||
| Body Surface Area | N/A | 0.22 (<0.05) | N/A |
| Systemic or Biologic therapy | N/A | 0.05 (0.58) | N/A |
| B: Spearman correlation Analyses of GlycA in the NIH Cohort. | |||
|---|---|---|---|
| Variable | Total Cohort | Psoriasis | Controls |
| (N=181) | (N=151) | (N=30) | |
| Demographic and Clinical Characteristics | |||
| Age | 0.08 (0.31) | −0.003 (0.95) | 0.24 (0.19) |
| Gender | 0.05 (0.49) | 0.09 (0.06) | −0.23 (0.22) |
| Hypertension | 0.01 (0.86) | −0.03 (0.52) | 0.21 (0.28) |
| Type 2 DM | 0.03 (0.67) | 0.01 (0.81) | 0.19 (0.31) |
| Hyperlipidemia | 0.28 (0.08) | 0.08 (0.08) | 0.24 (0.2) |
| Metabolic Syndrome | 0.14 (0.009) | 0.11 (0.02) | 0.15 (0.46) |
| Waist-to-Hip ratio | 0.16 (0.03) | 0.23 (<0.001) | 0.1 (0.36) |
| Tobacco | 0.12 (0.11) | 0.11 (0.07) | 0.18 (0.3) |
| Current Smokers | 0.08 (0.06) | 0.06 (0.20) | 0.25 (0.19) |
| Statin use | 0.01 (0.9) | 0.01 (0.89) | No correlation |
| Clinical and Laboratory Values | |||
| Body mass index | 0.29 (0.001) | 0.32 (0.001) | 0.20 (0.03) |
| Systolic blood pressure | 0.15 (0.04) | −0.01 (0.91) | 0.24 (0.2) |
| Diastolic blood pressure | 0.07 (0.37) | −0.02 (0.65) | 0.29 (0.12) |
| Total Cholesterol | 0.06 (0.16) | 0.01 (0.75) | 0.29 (0.12) |
| Low-Density Lipoprotein cholesterol | 0.12 (0.09) | 0.16 (<0.001) | 0.17 (0.37) |
| High-Density Lipoprotein cholesterol | −0.14 (<0.007) | −0.17 (<0.001) | −0.11 (<0.01) |
| Triglycerides | −0.02 (0.78) | −0.02 (0.70) | 0.36 (0.04) |
| Apolipoprotein A1 | −0.13 (<0.001) | −0.20 (<0.001) | −0.14 (0.02) |
| Apolipoprotein B | 0.17 (0.02) | 0.17 (0.002) | 0.23 (0.2) |
| Glucose | 0.13 (0.09) | 0.06 (0.19) | 0.20 (0.3) |
| Framingham risk score | 0.12 (0.1) | 0.11 (0.04) | 0.18 (0.42) |
| Insulin | 0.24 (<0.001) | 0.25 (<0.001) | 0.28 (0.02) |
| HOMA-IR | 0.24 (<0.001) | 0.23 (<0.001) | 0.28 (0.03) |
| hsCRP | 0.46 (<0.001) | 0.50 (<0.001) | 0.51 (0.01) |
| Psoriasis Details | |||
| PASI score | 0.57 (<0.001) | 0.57 (<0.001) | N/A |
| Body Surface Area affected | 0.43 (<0.001) | 0.43 (<0.001) | N/A |
| Systemic or Biologic Treatment | −0.12 (0.04) | −0.12 (0.04) | N/A |
| Vascular Inflammation by FDG PET/CT | |||
| Aortic Vascular Inflammation | 0.33 (<0.001) | 0.32 (<0.001) | 0.27 (0.008) |
| Coronary Plaque Burden by CCTA | |||
| Total Burden of Coronary Artery Disease | 0.20 (<0.001) | 0.30 (<0.001) | 0.19 (<0.001) |
Values are expressed as Rho (p value) for all variables.
DM: Diabetes Mellitus, HOMA-IR: Homeostasis Model Assessment of Insulin Resistance, Hs-CRP: high-sensitivity C-reactive protein, PASI: Psoriasis Area Severity Index.